Prometheus Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress - Both topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results expected concurrently in 4Q 2022 - - Bioavailability greater than 80% achieved upon completion of PRA023 subcutaneous bridging...